Fenwick & West advised Stoke Therapeutics on the offering, Wilson Sonsini Goodrich & Rosati advised Stoke on IP matters and Davis Polk & Wardwell advised the...
Stoke Therapeutics’ $125 Million Upsized Common Stock Offering
Third Harmonic Bio’s $213.1 Million IPO
Fenwick represented Third Harmonic Bio, Inc. on the deal. Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT...
Impel NeuroPharma’s $80 Million Initial Public Offering
Fenwick & West LLP advised Impel NeuroPharma on the deal. Impel NeuroPharma, a late-stage pharmaceutical company developing transformative therapies for diseases of the central nervous system, announced its...
AKASA’s $60 Million Series B Financing
Fenwick & West LLP advised AKASA on the deal. AKASA (formerly known as Alpha Health), the only Unified Automation™ company for revenue cycle management in healthcare,...
Icertis’ $80 Million Series F Round
Fenwick & West LLP advised Icertis on the deal. Icertis, a contract intelligence company that pushes the boundaries of what’s possible with contract lifecycle management, announced its...